Mega-Trial Blends Lifestyle, GLP-1 Drugs to Halt Alzheimer's Cognitive Decline
The Alzheimer's Association has just launched a groundbreaking $100 million global clinical trial, named the PROTECT-Cog Study, aiming to prevent cognitive decline and dementia by combining proven lifestyle changes with GLP-1 agonist drugs. Announced at the Alzheimer's Association International Conference (AAIC) 2026 in London, this ambitious three-year study represents a significant leap in prevention science, targeting at-risk older adults with a dual approach to safeguard their brain health before symptoms take hold.

















